eLetters

117 e-Letters

published between 2010 and 2013

  • Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Comment on the article of Vincent et al.
    Alfons A den Broeder

    Dear Editor,

    Vincent et al present a thorough review of available clinical research on antidrug antibodies to tumour necrosis factor blocking agents (1). We agree to a large extent with their interpretation of the data with regard to pathofysiology, assay characteristics and variation in drug and antidrug antibody serum levels. However, the conclusion that measurement of (anti)drug levels should therefore be used f...

    Show More
  • Erdheim-Chester disease
    Albert Selva-O'Callaghan

    Dear Editor,

    We read with interest the excellent study published by Cavalli et al.1 in ARD and would like to voice some considerations. Although heterogeneity is the rule in the clinical presentation of patients with Erdheim-Chester disease (ECD), some manifestations should be regarded as diagnostic triggers of this condition. The presence of unexpected interstitial lung disease on chest radiography, a coated aorta...

    Show More
  • Which ultrasound method has the upper hand in the follow-up of the patients with recurrent carpal tunnel syndrome?
    Antonios Kerasnoudis

    Dear Editor,

    I read with great interest the study of different diagnostic ultrasound measures of median nerve volume in patients with carpal tunnel syndrome (CTS) by Dejaco et al. (1). It is of great value, in my opinion, that this study succeeded not only in highlighting the diagnostic value and good reliability of ultrasound determination of median nerve cross sectional area (CSA) in patients with suspected CT...

    Show More
  • Herpes zoster infection risk in patients with rheumatoid arthritis on tumor necrosis factor inhibitors Prabha Ranganathan MD, MS
    PRABHA RANGANATHAN

    Dear Editor,

    We read with interest the study conducted by Galloway and colleagues on the risk of skin and soft tissue infections (SSTI) and herpes zoster (HZ) in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) antagonists versus non-biologic disease-modifying anti-rheumatic drugs (nbDMARDs). (1) This study highlights the occurrence of common infections such as SSTI and more unco...

    Show More
  • Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with Giant Cell Arteritis? Comment on the paper of Espigol-Frigole et al.
    Maxime Samson
    Dear editor,

    We have read with interest the recently published paper of Espigol-Frigole et al. 1 in which the authors confirmed that IL-17 is highly expressed in giant cell arteritis (GCA) lesions.1-3 They also demonstrated for the first time that IL-17 expression in temporal artery biopsies (TAB) was correlated with a better outcome. Among other interesting results, the identification of Foxp3+IL-17+ T cells by confocal micro...

    Show More
  • Comment on the article by Clowse, et al.
    Ryo Rokutanda

    Dear Editor,

    Clowse et al.[1] report that ferritin, oestradiol, and uric acid level at mid-gestation may predict preterm delivery in systemic lupus erythematosus (SLE) with mild-moderate disease activity. This is a well- done study, but we believe that the authors fail to fully address the effect of antiphospholipid antibodies. The author states that four patients tested positive for antiphospholipid antibodies....

    Show More
  • TNF antagonists and Shingles: Is Vaccination Advisable?
    Muhammad K Nisar

    Dear Editor,

    We read with interest the report by Galloway et al on the risk of skin and soft tissue infections (including shingles) in patients exposed to TNF antagonists from the BSRBR [1]. In the light of our recently published systematic literature review of the risk of shingles in rheumatoid arthritis (RA) patients, we would like to address several issues raised in the report [2]. The authors state that the inci...

    Show More
  • Step up therapy remains an appropriate option
    Duncan R Porter

    Dear Editor,

    I congratulate the research team from Rotterdam for the high quality study design of the tREACH study, but their conclusions are over-stated [1]. Their quotation of the literature is incomplete, referring to studies that have studied initial combination DMARDs plus corticosteroid (BeSt, FinRACo, COBRA) but excluding those studies that do not support their conclusions. There have been two previously publ...

    Show More
  • BAFF levels in association with response to TNFa antagonists; comment on the article by Genovese et al
    Athina Pyrpasopoulou

    Triantafyllou Areti, Pyrpasopoulou Athina, Anyfanti Panagiota, Balaska Ekaterini, Aslanidis Spyros, Douma Stella

    2nd Propedeutic Dept of Internal Medicine, Hippokration GH, Thessaloniki, Greece

    Dear Editor,

    We read with great interest the article by Genovese et al on the effect of the BAFF antagonist tabalumab in rheumatoid arthritis patients with inadequate response to TNFa blockade. The res...

    Show More
  • Improvement in Gout Management by Non-Rheumatologists Following Introduction of Guidelines
    Swan S Yeap

    Dear Editor,

    We read with interest the article by Doherty et al [1] where they lament suboptimal care of patients with gout, as the majority are managed by non-specialists. In 2005, we had surveyed non-rheumatologists on their practices regarding the management of gout [2]. Of the 128 respondents, 52.3% were general practitioners (GPs). A significant proportion of respondents were treating gout sub-optimally; 50% w...

    Show More

Pages